Ultra-Hypofractionated Radiotherapy for Early-Stage Glottic Cancer: Real-World Data From a Single Center

早期声门癌的超低分割放射治疗:来自单中心的真实世界数据

阅读:1

Abstract

BACKGROUND: In recent years, smaller-volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra-hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients. METHODS: This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35-42.5 Gy in 5 fractions. RESULTS: On a 59-month median follow-up, the 5-year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5-year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV(D98) (> 41.08 Gy) was found to be statistically significant in surgery-needed events (HR: 22.4, 95% CI: 1.9-252.1, p = 0.01). CONCLUSION: Single-cord ultra-hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。